Meet SimBioSys
Value Proposition
SimBioSys utilizes MRI-derived digital twins and biophysics-driven AI to model tumor biology and predict recurrence risk, providing a non-invasive alternative to genomic tests. With FDA-cleared TumorSight™ Viz and upcoming TumorSight™ Risk, SimBioSys provides surgeons with actionable, patient-specific insights.
Stacey Stevens
President & CEO
About
SimBioSys is a precision-medicine company using advanced AI and spatial biophysics to model tumors in 3D, giving clinicians deeper insight into tumor behavior and improving treatment planning for cancer patients.
Highlights
- FDA-Cleared Clinical Platform: Foundational application TumorSight™ Viz with three FDA clearances secured.
- Adopted by Leading Cancer Centers: TumorSight™ Viz is deployed at Mayo Clinic, MD Anderson, Emory, Stanford, and Memorial Sloan Kettering, with enterprise-level rollout initiated at Mayo Clinic in Arizona.
- Expanding Access & Equity: TumorSight™ Risk helps close gaps in recurrence assessment for underserved and high-risk patient groups.
Why We Invested
Our Investment in SimBioSys is driven by its clinically validated imaging platform and its ability to address unmet gaps left by existing genomic testing. The leadership team’s credibility, experience, and deep clinical partnerships position the company as a potential category leader in AI-based cancer decision support. SimBioSys’s MRI-derived digital twin technology offers a non-invasive, cost-efficient, and more accessible approach to characterizing tumor biology and assessing recurrence risk, thereby enhancing decision-making for both surgeons and oncologists. Supported by growing clinical adoption at major cancer centers, we see a clear opportunity to support a company reshaping the future of precision oncology.